サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1650945

ゲノム編集／ゲノム工学の世界市場

Genome Editing / Genome Engineering

出版日
ページ情報
英文 187 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ゲノム編集／ゲノム工学の世界市場
出版日: 2025年02月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ゲノム編集／ゲノム工学の世界市場は2030年までに382億米ドルに達する

2024年に129億米ドルと推定されるゲノム編集／ゲノム工学の世界市場は、2024～2030年の分析期間においてCAGR 19.8%で成長し、2030年には382億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるCRISPR技術は、CAGR 22.2％を記録し、分析期間終了までに187億米ドルに達すると予測されます。ZFN技術セグメントの成長率は、分析期間でCAGR 14.8％と推定されます。

米国市場は38億米ドルと推定、中国はCAGR19.0%で成長すると予測

米国のゲノム編集／ゲノム工学市場は、2024年に38億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに58億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは19.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ17.6%と16.1%と予測されています。欧州では、ドイツがCAGR約13.2%で成長すると予測されています。

世界のゲノム編集／ゲノム工学市場- 主要動向と促進要因のまとめ

ゲノム編集はなぜ医療、農業、バイオテクノロジーに革命をもたらすのか？

ゲノム工学としても知られるゲノム編集は、科学的イノベーションの最前線にあり、医療、農業、バイオテクノロジーにおいて前例のない可能性を提供しています。しかし、なぜゲノム編集が今日の状況において革命的なのだろうか？この技術によって、科学者は生物のDNAに正確で的を絞った変更を加えることができ、遺伝的欠陥の修正、望ましい形質の強化、新たな生物学的機能の創出が可能になります。CRISPR-Cas9、TALEN、ジンクフィンガーヌクレアーゼなどの技術により、研究者たちは比類のない精度と効率で特定の遺伝子を改変することができるようになり、遺伝性疾患の治療から農作物の回復力の向上まで、あらゆるアプローチに変革をもたらすようになった。

医学の分野では、ゲノム編集は、嚢胞性線維症、鎌状赤血球貧血、筋ジストロフィーなどの遺伝性疾患の原因となる欠陥遺伝子を直接修正することで、これらの疾患を治癒する可能性を秘めています。この技術はがん治療にも応用が検討されており、免疫細胞を改変してがん細胞をより効果的に標的にして破壊することができます。農業分野では、ゲノム編集は害虫や病気、環境ストレスに強い作物の開発に役立っており、気候変動に直面した際の食糧安全保障を向上させています。バイオテクノロジーでは、この技術によって新規形質を持つ遺伝子組み換え生物（GMO）の創出が可能になり、医薬品、バイオ燃料、工業用酵素などの産業に革命をもたらしています。生きている生物の遺伝子構成を根本的に変える能力を持つゲノム編集は、さまざまな分野の未来を形作り、現代で最も影響力のある科学的進歩の一つとなっています。

技術の進歩によってゲノム編集はどのように精密化し、利用しやすくなっているのか？

技術の進歩により、ゲノム編集の精度、効率、利用しやすさが大幅に改善され、研究や臨床応用のための強力なツールとなっています。この分野における最も画期的な革新のひとつは、ゲノム工学の状況を一変させた遺伝子編集技術であるCRISPR-Cas9の開発です。CRISPR-Cas9は、ガイドRNAを使ってCas9酵素をゲノムの特定の場所に誘導し、そこで正確な切断を行うことで、高度に標的化されたDNA改変を可能にします。このシステムは、従来のゲノム編集法よりも高速で効率的であるだけでなく、遺伝子のノックアウトから新しい配列の挿入まで、幅広い遺伝子改変を可能にする柔軟性も備えています。

最近のCRISPR技術の進歩は、その精度と汎用性をさらに高めています。例えば、塩基編集やプライム編集技術の開発により、科学者は二本鎖切断を起こすことなくゲノムに一塩基の変化や小さな編集を加えることができるようになり、意図しない変異やオフターゲット効果のリスクが減少しました。これらの進歩は、正確さが最も重要な治療応用において特に有用です。さらに、CRISPRの汎用性は、研究者が特定の生物学的プロセスや疾患に関与する遺伝子を同定するための大規模な遺伝子スクリーニングを行うことを可能にする「CRISPRライブラリー」の作成によって拡大しました。

もうひとつの大きな進歩は、ゲノム編集ツールへのアクセスが容易になったことです。CRISPR-Cas9とその関連技術は広く利用できるようになり、市販のキットやオープンソースのプラットフォームによって、世界中の研究者がゲノム編集にアクセスしやすくなった。これらのツールの簡便さと手頃な価格は、遺伝子研究を民主化し、かつては資金力のある研究所に限られていた最先端の研究を、小規模な研究所や研究機関でも行えるようにしました。さらに、ウイルスベクターやナノ粒子などの送達システムの進歩により、ゲノム編集成分を標的細胞に送達する効率が向上し、治療への応用がより現実的になっています。

さらに、ゲノム編集研究における人工知能（AI）と機械学習の統合は、標的外影響を予測し最小化する能力を高めています。AI主導のアルゴリズムは、膨大な遺伝子データを解析してより正確なガイドRNAを設計し、遺伝子編集の特異性を高めることができます。これは、意図しない改変を最小限に抑えることが安全性のために重要である臨床応用において特に重要です。このような技術の進歩により、ゲノム編集はより正確でスケーラブル、かつ利用しやすいものとなり、医療、農業、バイオテクノロジーにおける新たな可能性が開かれつつあります。

ゲノム編集はなぜ医療と農業の発展に不可欠なのか？

ゲノム編集は、ヒトの健康と食糧安全保障における重要な課題に対処するための標的を絞った介入を可能にするため、医療と農業の両方の発展に不可欠です。医学の分野では、ゲノム編集は、根本的な遺伝子変異を直接修正することによって、遺伝性疾患を治療し、さらには治癒させる可能性を提供します。嚢胞性線維症、ハンチントン病、血友病など、単一遺伝子の変異によって引き起こされる病気は、ゲノム編集療法の有力な候補です。CRISPR-Cas9のような技術を使って欠陥遺伝子を修復したり置き換えたりすることで、研究者は症状の管理にとどまらず、病気の根本原因に対処する新しい治療法を開発しています。例えば、鎌状赤血球貧血やβサラセミアなどの血液疾患については、CRISPRを用いた臨床試験がすでに進行中であり、これらの疾患の原因となる遺伝的欠陥の修正に有望な結果が示されています。

遺伝子疾患の治療に加えて、ゲノム編集はがん免疫療法にも応用されようとしています。CAR-T細胞療法のような治療法は、がん細胞をよりよく認識し攻撃するように患者の免疫細胞を改変するものであるが、これらの治療の特異性と有効性を向上させるために、ゲノム編集によって強化されつつあります。さらにゲノム編集は、幹細胞を改変して移植用の組織や臓器を作り出すことを可能にすることで、再生医療に革命をもたらす可能性を秘めており、臓器不全や重傷の患者に新たな希望をもたらしています。

農業の分野では、ゲノム編集は作物の回復力、収量、栄養価を高める上で重要な役割を果たしています。世界人口は2050年までに100億人近くに達すると予想されており、食糧安全保障はますます緊急の課題となっています。ゲノム編集によって、科学者は害虫や病気、干ばつや暑さなどの環境ストレス要因に強い作物を開発することができ、気候変動に直面しても食糧供給を確保できるようになります。例えば、CRISPRは病気に強い小麦、干ばつに強いトウモロコシ、保存性を高めたトマトの開発に利用されています。こうした進歩は、農家が化学農薬や化学肥料への依存を減らすだけでなく、作物の生産性を向上させ、より持続可能な農業に貢献します。

耐性と収量の向上に加えて、ゲノム編集は作物の栄養価を高めることができます。例えば、イネはCRISPRを用いて遺伝子組み換えされ、ビタミンAの前駆体であるβ-カロテンの濃度を高め、イネを主食とする地域のビタミン欠乏症に対処しています。同様に、油分やタンパク質の質を改善したり、その他の栄養価を高めたりしたゲノム編集作物は、栄養失調と闘い、世界中の公衆衛生を改善する可能性を秘めています。人間の健康と農業における喫緊の課題に対処することで、ゲノム編集は両分野に変革的な影響を与えることができます。

ゲノム編集市場の成長を促す要因とは？

バイオテクノロジーへの投資の増加、遺伝性疾患の有病率の上昇、CRISPRのようなゲノム編集技術の進歩など、ゲノム編集市場の急成長を後押ししている主な要因はいくつかあります。まず、民間と公的セクターの両方からの投資の急増が、ゲノム編集市場の成長に大きく寄与しています。製薬会社、ベンチャーキャピタル、政府機関は、ゲノム編集が医療、農業、産業に革命をもたらす可能性を認識し、ゲノム編集研究に資金を投入しています。このような資金の流入は、ゲノム編集療法や農業ソリューションの開発を加速させるとともに、送達システムやバイオインフォマティクスなどの関連技術の革新を促しています。

第二に、遺伝性疾患やがんの蔓延が進むにつれ、高度な治療ソリューションに対する需要が高まっています。疾患との遺伝的関連性がより多く特定されるにつれて、これらの病態を遺伝的根源から解決できる標的治療に対するニーズが高まっています。ゲノム編集は遺伝子変異を修正する直接的なアプローチを提供するため、遺伝性疾患からがんやウイルス感染症に至るまで、幅広い疾患の治療に魅力的な選択肢となります。こうした疾患を治癒させたり、経過を大きく変えたりできる可能性があることから、ゲノム編集療法への関心が高まり、市場の成長を後押ししています。

第三に、ゲノム編集技術の急速な進歩、特にCRISPR-Cas9の開発が市場の拡大を後押ししています。CRISPRは、ジンクフィンガーヌクレアーゼやTALENのような以前の技術に比べ、より効率的で手頃な価格の汎用性の高い遺伝子編集法を提供することで、ゲノム工学に革命をもたらしました。CRISPR技術が改良を続け、塩基エディターやプライムエディターのようなより精密な編集ツールが開発されるにつれて、ゲノム編集の潜在的な用途が拡大し、市場の成長をさらに促進しています。こうした進歩により、ゲノム編集は製薬から農業まで、より幅広い研究機関や産業で利用しやすくなっています。

さらに、個別化医療の台頭がゲノム編集市場の成長に大きな役割を果たしています。医療分野が患者の遺伝的体質に基づいてよりオーダーメイドの治療を目指すようになるにつれ、ゲノム編集はオーダーメイドの治療法を開発する上で重要なツールと見なされるようになっています。特定の遺伝子変異や経路を標的とした治療を設計できることから、臨床現場、特にがん治療や希少遺伝性疾患においてゲノム編集の魅力が高まっています。

規制当局の支援とゲノム編集の潜在的利益に対する一般市民の意識の高まりも市場拡大に寄与しています。FDAやEMAのような規制機関はゲノム編集に基づく治療を承認し始めており、主流のヘルスケアにおいてこれらの技術が受け入れられつつあることを示しています。さらに、メディア報道や科学的ブレークスルーに後押しされ、ゲノム編集に対する一般の認識が高まるにつれ、この技術に基づく治療法やイノベーションに対する需要も高まっています。

まとめると、ゲノム編集市場の成長の原動力は、バイオテクノロジーへの多額の投資、遺伝性疾患の有病率の上昇、CRISPRのようなゲノム編集技術の進歩、個別化医療へのシフト、規制当局の支援の高まりです。ゲノム編集が進化し続けるにつれて、医療、農業、バイオテクノロジーへの応用が拡大し、ヘルスケア、食品生産、科学研究の未来が形作られるであろう。

セグメント

技術（CRISPR、ZFN、TALEN、その他の技術）、送達方法（生体外、生体内）、用途（遺伝子工学、臨床応用）、最終用途（製薬・バイオテクノロジー企業、学術・政府研究機関、委託研究機関）

調査対象企業の例（全27件）

  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Horizon Discovery Group PLC
  • Integrated DNA Technologies（IDT）, Inc.
  • Lonza Group AG
  • Merck & Co., Inc.
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Sangamo Therapeutics
  • Thermo Fisher Scientific, Inc.
  • Transposagen Biopharmaceuticals, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP12163

Global Genome Editing / Genome Engineering Market to Reach US$38.2 Billion by 2030

The global market for Genome Editing / Genome Engineering estimated at US$12.9 Billion in the year 2024, is expected to reach US$38.2 Billion by 2030, growing at a CAGR of 19.8% over the analysis period 2024-2030. CRISPR Technology, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$18.7 Billion by the end of the analysis period. Growth in the ZFN Technology segment is estimated at 14.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.8 Billion While China is Forecast to Grow at 19.0% CAGR

The Genome Editing / Genome Engineering market in the U.S. is estimated at US$3.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.6% and 16.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.2% CAGR.

Global Genome Editing / Genome Engineering Market - Key Trends and Drivers Summarized

Why Is Genome Editing Revolutionizing Medicine, Agriculture, and Biotechnology?

Genome editing, also known as genome engineering, is at the forefront of scientific innovation, offering unprecedented possibilities in medicine, agriculture, and biotechnology. But why is genome editing so revolutionary in today's landscape? This technology allows scientists to make precise, targeted changes to an organism's DNA, enabling the correction of genetic defects, the enhancement of desirable traits, and the creation of new biological functions. Techniques like CRISPR-Cas9, TALENs, and zinc-finger nucleases have empowered researchers to modify specific genes with unmatched accuracy and efficiency, transforming the way we approach everything from treating genetic disorders to improving crop resilience.

In medicine, genome editing holds the promise of curing inherited diseases such as cystic fibrosis, sickle cell anemia, and muscular dystrophy by directly correcting the faulty genes responsible for these conditions. The technology is also being explored for cancer therapy, where it can be used to modify immune cells to target and destroy cancer cells more effectively. In agriculture, genome editing is helping develop crops that are more resistant to pests, diseases, and environmental stress, improving food security in the face of climate change. In biotechnology, this technology enables the creation of genetically modified organisms (GMOs) with novel traits, revolutionizing industries like pharmaceuticals, biofuels, and industrial enzymes. With its ability to fundamentally alter the genetic makeup of living organisms, genome editing is shaping the future of multiple sectors, making it one of the most impactful scientific advancements of our time.

How Are Technological Advancements Making Genome Editing More Precise and Accessible?

Technological advancements are significantly improving the precision, efficiency, and accessibility of genome editing, making it an even more powerful tool for research and clinical applications. One of the most groundbreaking innovations in this field is the development of CRISPR-Cas9, a gene-editing technology that has transformed the landscape of genome engineering. CRISPR-Cas9 allows for highly targeted DNA modifications by using a guide RNA to direct the Cas9 enzyme to a specific location in the genome, where it makes a precise cut. This system is not only faster and more efficient than previous genome editing methods, but it is also more flexible, allowing for a wide range of genetic modifications, from gene knockout to the insertion of new sequences.

Recent advancements in CRISPR technology have further enhanced its precision and versatility. For example, the development of base editing and prime editing techniques allows scientists to make single nucleotide changes or small edits to the genome without causing double-strand breaks, reducing the risk of unintended mutations or off-target effects. These advancements are particularly useful in therapeutic applications where precision is paramount. In addition, CRISPR's versatility has been expanded with the creation of "CRISPR libraries," which allow researchers to conduct large-scale genetic screens to identify genes involved in specific biological processes or diseases.

Another significant advancement is the increased accessibility of genome editing tools. CRISPR-Cas9 and related technologies have become widely available, with commercial kits and open-source platforms making genome editing more accessible to researchers worldwide. The simplicity and affordability of these tools have democratized genetic research, allowing smaller labs and institutions to engage in cutting-edge work that was once limited to well-funded laboratories. Additionally, advancements in delivery systems, such as viral vectors and nanoparticles, are improving the efficiency of delivering genome-editing components into target cells, making therapeutic applications more feasible.

Furthermore, the integration of artificial intelligence (AI) and machine learning in genome editing research is enhancing the ability to predict and minimize off-target effects. AI-driven algorithms can analyze vast amounts of genetic data to design more accurate guide RNAs, increasing the specificity of gene edits. This is particularly important for clinical applications, where minimizing unintended modifications is crucial for safety. These technological advancements are making genome editing more precise, scalable, and accessible, opening up new possibilities in medicine, agriculture, and biotechnology.

Why Is Genome Editing Essential for Advancing Medicine and Agriculture?

Genome editing is essential for advancing both medicine and agriculture because it enables targeted interventions that address critical challenges in human health and food security. In medicine, genome editing offers the potential to treat or even cure genetic diseases by directly correcting the underlying genetic mutations. Diseases like cystic fibrosis, Huntington's disease, and hemophilia, which are caused by single-gene mutations, are prime candidates for genome editing therapies. By using technologies like CRISPR-Cas9 to repair or replace defective genes, researchers are developing novel treatments that go beyond managing symptoms to address the root cause of the disease. For example, clinical trials using CRISPR-based therapies are already underway for blood disorders like sickle cell anemia and beta-thalassemia, showing promising results in correcting the genetic defects responsible for these conditions.

In addition to treating genetic disorders, genome editing is also being explored for cancer immunotherapy. Techniques like CAR-T cell therapy, which involves modifying a patient’s immune cells to better recognize and attack cancer cells, are being enhanced through genome editing to improve the specificity and effectiveness of these treatments. Moreover, genome editing has the potential to revolutionize regenerative medicine by enabling the modification of stem cells to generate tissues and organs for transplantation, offering new hope for patients with organ failure or severe injuries.

In agriculture, genome editing is playing a crucial role in enhancing crop resilience, yield, and nutritional value. With the global population expected to reach nearly 10 billion by 2050, food security is becoming an increasingly urgent issue. Genome editing allows scientists to develop crops that are resistant to pests, diseases, and environmental stressors such as drought and heat, helping to secure food supplies in the face of climate change. For example, CRISPR has been used to create disease-resistant wheat, drought-tolerant corn, and tomatoes with improved shelf life. These advancements not only help farmers reduce their reliance on chemical pesticides and fertilizers but also increase crop productivity, contributing to more sustainable agricultural practices.

In addition to improving resistance and yield, genome editing can enhance the nutritional value of crops. For example, rice has been genetically modified using CRISPR to increase its levels of beta-carotene, a precursor to vitamin A, addressing vitamin deficiencies in regions where rice is a staple food. Similarly, genome-edited crops with improved oil content, protein quality, or other nutritional enhancements have the potential to combat malnutrition and improve public health worldwide. By addressing some of the most pressing challenges in human health and agriculture, genome editing is positioned to have a transformative impact on both sectors.

What Factors Are Driving the Growth of the Genome Editing Market?

Several key factors are driving the rapid growth of the genome editing market, including increasing investment in biotechnology, the rising prevalence of genetic diseases, and advancements in genome editing technologies like CRISPR. First, the surge in investment from both the private and public sectors is significantly contributing to the growth of the genome editing market. Pharmaceutical companies, venture capital firms, and government agencies are pouring funds into genome editing research, recognizing its potential to revolutionize medicine, agriculture, and industry. This influx of capital is accelerating the development of genome-editing therapies and agricultural solutions, as well as driving innovations in related technologies like delivery systems and bioinformatics.

Second, the increasing prevalence of genetic diseases and cancer is creating a growing demand for advanced therapeutic solutions. As more genetic links to diseases are identified, there is a rising need for targeted treatments that can address these conditions at their genetic root. Genome editing offers a direct approach to correcting genetic mutations, making it an attractive option for treating a wide range of conditions, from inherited disorders to cancers and viral infections. The ability to potentially cure or significantly alter the course of these diseases is propelling the interest in genome-editing therapies, driving market growth.

Third, the rapid advancements in genome editing technologies, particularly the development of CRISPR-Cas9, are fueling the expansion of the market. CRISPR has revolutionized genome engineering by offering a more efficient, affordable, and versatile method for editing genes compared to earlier techniques like zinc-finger nucleases and TALENs. As CRISPR technology continues to improve, with the development of more precise editing tools like base editors and prime editors, the potential applications of genome editing are expanding, further driving the growth of the market. These advancements are making genome editing more accessible to a wider range of research institutions and industries, from pharmaceuticals to agriculture.

Additionally, the rise of personalized medicine is playing a major role in the growth of the genome editing market. As the medical field moves toward more tailored treatments based on a patient’s genetic makeup, genome editing is increasingly seen as a key tool in developing customized therapies. The ability to design treatments that target specific genetic mutations or pathways is enhancing the appeal of genome editing in clinical settings, particularly in cancer therapy and rare genetic disorders.

Regulatory support and increasing public awareness of the potential benefits of genome editing are also contributing to market expansion. Regulatory agencies like the FDA and EMA are beginning to approve genome editing-based therapies, signaling growing acceptance of these technologies in mainstream healthcare. Moreover, as public awareness of genome editing grows, driven by media coverage and scientific breakthroughs, there is increasing demand for therapies and innovations based on this technology.

In summary, the growth of the genome editing market is driven by significant investment in biotechnology, the rising prevalence of genetic diseases, advancements in genome editing technologies like CRISPR, the shift toward personalized medicine, and growing regulatory support. As genome editing continues to evolve, its applications in medicine, agriculture, and biotechnology will expand, shaping the future of healthcare, food production, and scientific research.

SCOPE OF STUDY:

The report analyzes the Genome Editing / Genome Engineering market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (CRISPR, ZFN, TALEN, Other Technologies); Delivery Method (Ex-Vivo, In-Vivo); Application (Genetic Engineering, Clinical Applications); End-Use (Pharma & Biotech Companies, Academic & Government Research Institutes, Contract Research Organizations)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 27 Featured) -

  • CRISPR Therapeutics AG
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Horizon Discovery Group PLC
  • Integrated DNA Technologies (IDT), Inc.
  • Lonza Group AG
  • Merck & Co., Inc.
  • New England Biolabs, Inc.
  • OriGene Technologies, Inc.
  • Sangamo Therapeutics
  • Thermo Fisher Scientific, Inc.
  • Transposagen Biopharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Genome Editing / Genome Engineering - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in CRISPR Technology Revolutionize Genome Editing Applications
    • Expansion of Genome Editing Applications in Agriculture and Livestock
    • Role of Genome Editing in Personalized Medicine and Therapeutic Development
    • Growth of Therapeutic Applications Driving Market Opportunities
    • Implications of Germline and Somatic Cell Editing
    • Future Directions: Genome Editing in Neurodegenerative Diseases and Cancer
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Genetic Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Genetic Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Clinical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Clinical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for CRISPR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for CRISPR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for ZFN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for ZFN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for TALEN by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for TALEN by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Ex-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Ex-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for In-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for In-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World 6-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 21: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 22: World 6-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 23: World Genome Editing / Genome Engineering Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Genome Editing / Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • CANADA
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • JAPAN
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • CHINA
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 54: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: China 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • EUROPE
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Genome Editing / Genome Engineering by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 70: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • GERMANY
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • ITALY
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 88: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Italy 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • UNITED KINGDOM
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 94: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: UK 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 96: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: UK 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 98: UK Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 100: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of Europe 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 102: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of Europe 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Genome Editing / Genome Engineering Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 108: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Asia-Pacific 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 112: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Asia-Pacific 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 116: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Application - Genetic Engineering and Clinical Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of World 6-Year Perspective for Genome Editing / Genome Engineering by Application - Percentage Breakdown of Value Sales for Genetic Engineering and Clinical Applications for the Years 2025 & 2030
    • TABLE 118: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Technology - CRISPR, ZFN, TALEN and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of World 6-Year Perspective for Genome Editing / Genome Engineering by Technology - Percentage Breakdown of Value Sales for CRISPR, ZFN, TALEN and Other Technologies for the Years 2025 & 2030
    • TABLE 120: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by Delivery Method - Ex-Vivo and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of World 6-Year Perspective for Genome Editing / Genome Engineering by Delivery Method - Percentage Breakdown of Value Sales for Ex-Vivo and In-Vivo for the Years 2025 & 2030
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Genome Editing / Genome Engineering by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Genome Editing / Genome Engineering by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Contract Research Organizations for the Years 2025 & 2030

IV. COMPETITION